Susan Groshen

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies”.

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.4787

N/A

0DataRank · unranked

16 citations

Vincent Chung, Joseph M. Tuscano, Tanya Siddiqi, Sagus Sampath, Jeff Longmate +3 more

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10500

N/A

0DataRank · unranked

4 citations

Meaghan Granger, Susan Groshen, Denice Tsao‐Wei, Anasheh Shamirian, Scarlett Czarnecki +15 more

Informed consent in phase I clinical trials: Implications for trends in design.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e14077

N/A

0DataRank · unranked

0 citations

Susan Groshen, Paul Frankel

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

Cancer Chemotherapy and Pharmacology(2021)10.1007/s00280-020-04224-8

N/A

0DataRank · unranked

22 citations

Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos +6 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

Clinical and biologic predictors of response to MIBG therapy: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e22003

N/A

0DataRank · unranked

0 citations

Katherine K. Matthay, Susan Groshen, Yueh‐Yun Chi, Meaghan Granger, Julie R. Park +3 more